Artiva Biotherapeutics (ARTV) grants CFO 220,000 RSUs as inducement

Rhea-AI Filing Summary

Huston Thad Allen reported acquisition or exercise transactions in this Form 4 filing.

Artiva Biotherapeutics’ Chief Financial Officer, Thad Allen Huston, received an equity award of 220,000 shares of common stock on March 10, 2026. The Form 4 describes this as a restricted stock unit grant under the company’s 2025 Inducement Plan, with no cash purchase price and resulting direct ownership of 220,000 shares.

Insider Trade Summary

Net Buyer: 220,000 shares

Net Buy 1 txn

Insider Huston Thad Allen

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	220,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 220,000 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock unit award granted under the Issuer's 2025 Inducement Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/10/2026 - 04:47 PM Learn about SEC filing dates

FAQ

What insider transaction did Artiva Biotherapeutics (ARTV) report for its CFO?

Artiva Biotherapeutics reported that its Chief Financial Officer, Thad Allen Huston, received an award of 220,000 shares of common stock. The transaction is classified as a grant or award, not a market purchase, and reflects equity-based compensation rather than a cash investment in shares.

How many Artiva Biotherapeutics (ARTV) shares does the CFO hold after this Form 4?

Following the reported transaction, Artiva’s CFO directly holds 220,000 shares of common stock. The entire amount comes from the reported restricted stock unit award, so this filing shows both the new grant and the resulting total direct ownership position at that same 220,000-share level.

Was the Artiva Biotherapeutics (ARTV) CFO’s 220,000-share award a stock purchase?

No. The 220,000 shares were reported with transaction code “A,” indicating a grant, award, or other acquisition. A footnote clarifies this is a restricted stock unit award under Artiva’s 2025 Inducement Plan, granted at a reported price of $0.00 per share as compensation.

What plan governed the CFO’s equity grant at Artiva Biotherapeutics (ARTV)?

The equity grant to Artiva Biotherapeutics’ CFO is described as a restricted stock unit award under the company’s 2025 Inducement Plan. This indicates the award is part of a specific inducement equity program, rather than a general employee stock plan or open-market share purchase.

Does the Artiva Biotherapeutics (ARTV) Form 4 show any insider share sales?

No insider sales appear in this Form 4. The filing shows a single acquisition transaction coded “A,” representing a grant or award of 220,000 restricted stock units. The summary data lists no sell transactions, gifts, tax withholdings, or derivative exercises in this particular report.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huston Thad Allen

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		A		220,000(1)	A	$0	220,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock unit award granted under the Issuer's 2025 Inducement Plan.

	/s/ Andrew Cronauer, Attorney-in-Fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.